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APOBEC3G (A3G) and APOBEC3F (A3F) reduce Vif-negative HIV-1 provirus formation and cause
disabling provirus G-to-A hypermutation in vitro. However, evidence conﬂicts about whether they
negatively impact Vif-positive HIV-1, or only enhance virus genetic diversity, in vivo. We studied
peripheral blood mononuclear cells (PBMC) from 19 antiretroviral-naı¨ve, HIV-infected adults: 12 long-
term non-progressors (LTNP) and 7 non-controllers (NC). Cells from LTNP had higher A3G and A3F
mRNA levels, lower provirus burden, and more A3G-hypermutated positions in provirus sequence than
cells from NC. A3G mRNA level was directly associated with its Hypermutation Index (HI) and inversely
associated with provirus burden. Plasma HIV-1 RNA levels were inversely associated with A3G
expression levels and with HI only among subjects who had HI41. A3G HI was not associated
with provirus burden. These results indicate that A3G deaminase-dependent activity above a threshold
level, and its deaminase-independent functions, contribute to decreasing Vif-positive virus replication
in vivo.
& 2012 Elsevier Inc. All rights reserved.Introduction
The APOBEC3 (A3) family of cytidine deaminases defends
against retrotransposition (Esnault et al., 2005; Schumacher
et al., 2008; Chiu et al., 2006) and are expressed in many cell
types and tissues (Koning et al., 2009; Refsland et al., 2010). Some
family members, particularly APOBEC3G (A3G) and APOBEC3F
(A3F), also restrict Vif-negative human immunodeﬁciency virus
type 1 (HIV-1) replication in vitro. HIV-1 Vif counteracts their
antiviral activity, however (Cullen, 2006; Goila-Gaur and Strebel,
2008; Harris and Liddament, 2004; Sheehy et al., 2002). Vif limits
the cellular content of A3s, and their activity in progeny viral
particles, by accelerating A3 degradation, as well as perhaps by
degradation-independent mechanisms (Marin et al., 2003; Mehle
et al., 2004; Opi et al., 2007; Yu et al., 2003). A3G and A3F differ in
their DNA targeting and mutational signatures, levels of expres-
sion, and sensitivity to Vif. Therefore, it is important to study the
effects on HIV-1 of G-to-A hypermutation caused by both deami-
nases (called ‘hypermutation’ here).
The presence of A3-mediated hypermutation in provirus DNA
from many HIV-1-infected subjects (Kieffer et al., 2005; Pace
et al., 2006) indicates that Vif-mediated protection from host-
mediated proviral DNA deamination is not absolute in vivo.
Hypermutation in vif (Simon et al., 2005) and env genesll rights reserved.
.edu (M. De Pasquale).(Knoepfel et al., 2010) of proviruses in vivo have been reported.
Some evidence is consistent with hypermutation partially
restricting wild-type, Vif-positive HIV-1 replication in vivo in a
minority of infected subjects (Pace et al., 2006; Land et al., 2008;
Vazquez-Perez et al., 2009; Amoedo et al., 2011). Physiologically
higher A3G function in Th1, relative to Th2, CD4þ T cells also
decreased HIV-1 replication in vitro despite the presence of Vif,
whether A3G was in the virion or in the target cell cytoplasm
(Vetter et al., 2009a). Since A3G and A3F also have non-deaminase
mediated mechanisms of antiviral activity (Luo et al., 2007;
Mangeat et al., 2003; Mbisa et al., 2010), provirus hypermutation
may not be the only outcome of their antiviral activity.
An alternative hypothesis is that A3 activities are not extensive
enough to impair Vif-positive HIV-1 replication in vivo. Some data
suggest that hypermutation in provirus facilitates HIV-1 escape
from immunological and pharmacological inhibition by increas-
ing the pool of genetic diversity available for recombination
(Simon et al., 2005; Mulder et al., 2008; Jern et al., 2009;
Fourati et al., 2010; Kim et al., 2010; Sadler et al., 2010).
In this formulation, A3 activity provides a favorable advan-
tage for Vif-positive HIV-1 and is not sufﬁcient to block its
replication. This hypothesis predicts that hypermutation is
either directly associated with, or not associated with, virus
replication.
There is potential for A3s to both impair and beneﬁt HIV-1
replication (Smith, 2011). Indeed, most studies of associations
in vivo between measures of A3G and A3F on the one hand,
and Vif-positive HIV-1 replication and immunodeﬁciency pro-
gression on the other hand, have supported an anti-HIV effect
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different subject populations and used different metrics. Mea-
sures of A3G and/or A3F have involved their RNA levels with or
without cellular activation (Cho et al., 2006; Jin et al., 2005),
quantitation of hypermutation in cellular HIV-1 genomes (Pace
et al., 2006; Land et al., 2008; Ulenga et al., 2008a; Piantadosi
et al., 2009; Vazquez-Perez et al., 2009; Amoedo et al., 2011) or
both (Gandhi et al., 2008; Vazquez-Perez et al., 2009). Parameters
of HIV-1 replication have included HIV-1 plasma viral load, blood
CD4þ T cell count or immunodeﬁciency progression classiﬁca-
tion. Subjects have been compared across immunodeﬁciency
progression categories such as elite suppressors who have stable
CD4 cells with consistently undetectable HIV-1 viremia in
absence of any antiretroviral therapy (ART), long-term non-
progressors (LTNP), who have stable CD4 cells with, at most,
low-level HIV-1 viremia in the absence of any ART, and untreated
HIV-1 infected subjects with the more typical pace of progression
(non-controllers, NC). Some studies only examined untreated
subjects with typical progression (Cho et al., 2006; Piantadosi
et al., 2009; Ulenga et al., 2008b), or compared those who
spontaneously control HIV to subjects suppressed on HAART
(Gandhi et al., 2008). Genetic variations in Vif (Alexander et al.,
2002; Farrow et al., 2005; Pace et al., 2006) and A3G (An et al.,
2004; Pace et al., 2006) have been associated with degree of
hypermutation and/or HIV immunodeﬁciency progression. Sev-
eral groups have recently identiﬁed lower provirus burden and
cell-intrinsic mechanisms that limit HIV replication in elite
suppressors (Graf et al., 2011; Saez-Cirion et al., 2011; Buzon
et al., 2011); however, A3s were not evaluated in those control-
lers. We evaluated PBMC A3G and A3F mRNA levels and provirus
hypermutation, and assessed their associations with cellular
provirus burden in PBMCs and plasma HIV-1 RNA levels in
subjects who either did (LTNP), or did not (non-controllers, NC),
spontaneously control HIV-1. The results of this study extend
earlier reports and may help explain their conﬂicting results.Fig. 1. A3G and A3F expression levels are higher in peripheral blood mononuclear cel
(A) A3G and (B) A3F RNA levels from 12 LTNP (squares) and 7 NC (triangles). Bars repre
copy number strongly and signiﬁcantly correlates with A3F RNA copy number. SpearmResults
A3 mRNA levels and hypermutations in PBMCs from LTNP and NC
subjects
A3G and A3F mRNA levels were signiﬁcantly higher in PBMC
from the LTNP than in those from the NC subjects (Fig. 1A and B).
Mean log transformed A3G RNA copies/ng total RNA was higher in
the LTNP group than in the NC group (p¼0.015, Student’s t test).
Similarly, the mean A3F RNA level in LTNP subjects was higher
than the mean among NC subjects (p¼0.0178, Student’s t test).
There was a strong and signiﬁcant correlation between the
expression of A3G and A3F (Spearman r¼0.94, po0.0001), con-
sistent with the known co-regulation of their transcription
(Fig. 1C).
Population sequences of vif ampliﬁed from high molecular
weight PBMC DNA of 17 subjects were used to determine the
magnitude of A3-mediated cytidine deaminase enzymatic activity
in vivo, relative to each subject’s reference sequence, represented
by a non-hypermutated sequence from plasma HIV-1 RNA of the
same subject. Sequences from two LTNP subjects with plasma
HIV-1 RNAo50 copies/ml were not evaluable. G-to-A mutations
in both the A3G and A3F signature dinucleotide contexts, GG and
GA respectively, were quantiﬁed as an overall Hypermutation
Index (HI) that corrected for sequence length and RT error rate
(estimated as A-to-G mutation) (Kijak et al., 2007).
A3-mediated hypermutated positions in vif sequences were
more numerous among the LTNP than the NC subjects (77 among
the LTNP versus 12 among the NC subjects, p¼0.04, Mann-
Whitney U) (Fig. 2). Five of 10 (50%) of the LTNP subjects had a
dominant PBMC vif sequence with a hypermutation index (HI41)
and premature stop codons, while 2 of 7 (29%) of NC had HI41
and premature stop codons (not signiﬁcant, Fisher’s exact test)
(Supplemental Fig. 1A,B) (Kijak et al., 2007; Kijak et al., 2008).
Analyses using Hypermut 2.0 software were consistent with thels (PBMC) of long term non-progressor (LTNP) than non-controller (NC) subjects.
sent mean7SD of values and p value is computed by Student’s t test. (C) A3G RNA
an correlation coefﬁcient and p value are listed.
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hypermutation relative to their own reference sequence. Popula-
tion sequences of proviral PR and RT in a subset of these same
subjects also showed a higher percentage of subjects with pre-
dominant G-to-A hypermutated provirus among LTNPs than NCs.
Analyses of clonal sequences of vif were also performed from
PBMCs of 3 of the subjects described above, including 2 LTNP
(#40 and #31) and 1 NC (#44), and compared to results of theNC
32 DNA vif*
91 DNA vif*
LTNP
BASES
05 DNA vif*
31 DNA vif*
40 DNA vif*
02 DNA vif
38 DNA vif
60 DNA vif
25 DNA vif
67 DNA vif
44 DNA vif* 
07 DNA vif*
42 DNA vif
47 DNA vif
48 DNA vif
56 DNA vif
76 DNA vif
Fig. 2. Alignments of vif proviral sequences from LTN and NC subjects indicate
more APOBEC3-mediated hypermutations in some LTNP. Population sequence for
each subject was aligned to its own non-hypermutated reference sequence and
analyzed by Hypermut 2.0 (Rose and Korber, 2000) and HyperPack (Kija\\k et al.,
2007). Bars indicate positions with G-to-A substitutions in a context recognized by
APOBEC3G or APOBEC3F. * in right column marks 7 sequences with a Hypermuta-
tion Index (HI) 41 (5 from LTNP and 2 from NC subjects).
Fig. 3. Dinucleotide context of hypermutations in subjects with vif HI41. (A) The 7 seq
having hypermutations in the A3G dinucleotide context (GG HI) or the A3F dinuc
hypermutation), and 2 also had some degree of GA HI (A3F-mediated hypermutation). (B
p value are listed.population sequencing. All 13 vif clones from one LTNP (#40) had
very high HI (6.1–6.5), and the other LTNP (#31) had 27% of
clones with HIs from 1.53 to 2.38 (Supplemental Fig. 1C). Only
one vif clone out of 18 (5%) sequenced from the NC (#44) subject
had an HI41; this was one of the NC subjects identiﬁed with
HI41 in the population PCR product analysis (Supplemental
Fig. 1C). The cloned PCR product sequences thus were in excellent
agreement with HIs determined from population sequences for
those subjects (Supplemental Fig. 1A). Numbers of stop codons
were also similar in both population (Supplemental Fig. 1B) and
clonal sequences from each of these 3 subjects (Supplemental
Fig. 1D). Because of this validation, further cloned PCR product
analyses were not performed here.
Hypermutations in the 7 subjects with an overall HI41 were
also classiﬁed as either within GG dinucleotides targeted by A3G
(GG HI) or within GA dinucleotides targeted by A3F (GA HI)
(Fig. 3A). All 7 of these hypermutated sequences had A3G-speciﬁc
mutations, with GG HI ranging from 0.85 to 2.5. A3G’s GG HI
strongly correlated with A3G RNA expression in PBMCs (Spear-
man r¼0.7, p¼0.02) (Fig. 3B). Thus, higher A3G expression was
strongly and signiﬁcantly associated with more hypermutation in
provirus DNA, among those subjects in whom provirus hypermu-
tation was detected. This analysis was not possible for A3F as
A3F-speciﬁc mutations were additionally present in only 2 of
these subjects who were both LTNP (Fig. 3A). It is of note that the
highest magnitude of hypermutation observed here was a vif
sequence with a GA HI of 5 from a LTNP subject.
Among the subjects who had sequences of PR, RT, and vif genes
analyzed, HIs generally increased as follows: PRoRTovif sequences
(Table 1). This is consistent with the previously described gradient
in the HIV genome related to duration of a single-stranded DNA
intermediate during reverse transcription (Yu et al., 2004; Suspene
et al., 2006).uences with HI41 in proviral vif population sequences were further categorized as
leotide context (GA HI). All 7 had some magnitude of GG HI (A3G-mediated
) GG HI correlates with A3G RNA expression. Spearman correlation coefﬁcient and
Table 1
Hypermutation index (HI) in PR, RT and vif population sequences. A gradient with
increasing HI across these genome segments is seen in most subjects, consistent
with earlier reports that hypermutation increases, as follows: PRoRTovif. HI41
is indicated in bold.
Subject PR HI RT HI vif HI
LTNP 5 0.34 0.39 2.2
LTNP 31 1.7 0.39 3.4
LTNP 32 0 0.52 2.7
LTNP 40 2 – 6.46
LTNP 91 0.67 1.18 2.2
NC 7 1.35 1.44 1.36
NC 42 0.67 0.39 0.51
NC 44 1 0.39 2.04
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We assessed HIV-1 provirus copy numbers in vivo by an alu-
PCR assay modiﬁed from that described by O’Doherty et al.
(2002). High molecular weight PBMC DNA was separated from
nonintegrated viral DNA and used as the input template to
enhance speciﬁcity for provirus. A detection limit of 1 copy per
million cells allowed quantiﬁcation of provirus in PBMCs from all
17 subjects who also had vif population sequence obtained. The
amount of provirus in PBMC was quite stable over up to 15
months in 11 of the 13 subjects with specimens available from
two time points, consistent with the known stability of provirus
level (Supplemental Fig. 2).
There was signiﬁcantly less integrated provirus in PBMC of
the LTNP than the NC subjects (Fig. 4A, median¼10.2 versus 616
copies per million PBMC respectively, po0.0001). Higher A3G
mRNA levels in PBMCs correlated with fewer integration events
(r¼0.45, p¼0.05) (Fig. 4B). A3F mRNA levels did not correlate
with provirus burden (r¼0.34, p¼0.15) (Fig.4C).Associations of plasma HIV-1 RNA levels with provirus, A3 expression,
and hypermutation
We also evaluated associations of plasma viremia level with
provirus burden and A3 parameters. Provirus burden strongly and
signiﬁcantly correlated with the viral load in plasma (r¼0.76,
Spearman’s rank¼0.0002) (Fig. 5A). A3G and A3F mRNA levels at
the initial time point studied for each subject were inversely
correlated with plasma HIV-1 RNA levels (A3G: r¼0.59;
p¼0.0078; A3F: r¼0.56; p¼0.013) (Fig. 5B and C). Longitudinal
changes in A3 transcript levels were assessed over a maximum of
15 months in 12 of the subjects who had specimens available at
two time points. A3G and A3F levels did not vary over time in
6 out of 12 individuals’ cells. Changes in A3G RNA levels wereFig. 4. Alu-PCR quantitation of HIV provirus from high molecular weight PBMC DNA of
integrated HIV provirus than do PBMC of the 7 NC. Shown are mean7SD for each grou
inversely with provirus copy number in PBMCs. (C) A3F RNA copy number does not cor
p value are listed in B and C.found in the other 6, with substantial changes only in 3 (deﬁned
as more than a 5-fold increase or decrease mRNA level at the later
time-point). These longitudinal variations were inversely asso-
ciated with changes in plasma viral load in each subject (Fig. 5D).
This is consistent with A3 expression levels being inversely
associated with viral load and supporting an A3 antiviral effect.
Plasma viral load was also strongly inversely correlated
with the overall HI of vif population sequences, the measure of
A3-speciﬁc hypermutations in proviruses (r¼0.98, Spearman
p¼0.0004) (Fig. 6A). This is consistent with a physiological
antiviral effect of A3G cytidine deaminase-mediated editing of
provirus. However, if the analysis was performed including all
subjects, counting also those with GG HIo1, the correlation
between HI and plasma HIV-1 RNA level was not signiﬁcant (data
not shown). This result supports the hypothesis that A3G hyper-
mutation is associated with viral load only if it is above a
threshold level, which is present in some and not all subjects.
The overall HI of vif population sequences for subjects with
HI41, in contrast, did not correlate with provirus burden
(r¼0.14, p¼0.78) (Fig. 6B). These results suggest the hypothesis
that a non-deaminase mediated activity of A3G, and not its
cytidine deaminase enzyme activity, is responsible for the inverse
association between A3G expression and provirus burden.Hypermutation is not associated with amino acid polymorphisms in
Vif functional motifs
Distinct motifs in Vif have been mapped that are critical for its
interaction with A3G and/or A3F that leads to A3 degradation
(Dang et al., 2009; Donahue et al., 2008; Goila-Gaur and Strebel,
2008; He et al., 2008; Iwabu et al., 2010; Russell and Pathak,
2007). We analyzed a putative translation of the non-hypermu-
tated reference HIV-1 vif sequences from each subject, which
represented their dominant replication-competent genome, forLTNP and NC subjects. (A) PBMC of the12 LTNP have signiﬁcantly fewer copies of
p and p value computed by Student’s t test. (B) A3G RNA copy number correlates
relate with provirus copy number in PBMCs. Spearman correlation coefﬁcient and
Fig. 6. Hypermutation Index (HI) in proviral vif population sequences determined using HyperPack and measures of HIV burden among the 7 subjects with HI41. (A) HI
strongly correlates inversely with plasma viral load among subjects with HI41 in proviral vif population sequences. LTNP sequences are depicted by open circles; NC
sequences by closed squares. Spearman correlation coefﬁcient is 0.98 and p value¼0.0004. In contrast, no signiﬁcant correlation was seen when all 17 subjects, with and
without HI41 were included in the analysis. (B) Provirus burden was not signiﬁcantly associated with vif HI either among subjects with HI41 or all subjects (latter not
shown). LTNP sequences depicted by open circles, NC sequences by closed squares. Spearman correlation coefﬁcient and p value are listed.
Fig. 5. Associations of plasma HIV-1 RNA levels with provirus copies and A3G/F expression levels. (A) HIV plasma viral load is directly associated with integrated proviral
copy number. Values are log-transformed because of the wide range. (B) Plasma HIV RNA copy number is inversely correlated with A3G RNA copy number in PBMCs.
(C) Plasma HIV RNA copy number is inversely correlated with A3F RNA copy number in PBMCs. APOBEC3G/F RNA expression was determined by qRT-PCR and expressed as
A3G/F RNA copies per ng RNA in B and C. Spearman correlation coefﬁcient and p value are listed for A, B and C. (D) Longitudinal changes in A3G and F RNA and plasma viral
load were studied in 6 subjects who had specimens available at 2 time-points within 15 months. In each case, changes in A3G/F RNA were in the direction opposite to
changes in viral load.
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of A3G and/or A3F. This determined if Vif variation in its capacity
to degrade A3s was associated with the observed magnitude of
hypermutation. Vif SOCS Box (144SLQYLA149) and Zn-binding
motifs that are critical for degrading A3G and A3F by bridging to
the cellular E3 ubiquitin ligase complex (Yu et al., 2003) were
conserved in all non-hypermutated sequences. The Vif multi-
merization motif 161PPLP164, which is necessary for A3G binding
and degradation (Bernacchi et al., 2011; Miller et al., 2007), was
also preserved in all sequences. We also did not identify amino
acid polymorphisms in other motifs involved in Vif binding
to A3G or A3F, including 21WxSLVK26 and 40YRHHY44, that
are involved in interaction with A3G, and 11WxxDRMR17 and
74TGERxW79, that are essential for binding to A3F (Tian et al.,
2006). Polymorphisms in A3G binding sites were seen in 2 singleclonal sequences of vif from one LTNP (LTNP 31) (K26I and Y44H),
but neither of these polymorphisms in vif was present in the
population-based sequence or any of the other 36 non-hypermu-
tated clones from that subject.Discussion
The current results add support for an antiviral effect of A3G
against Vif-positive HIV-1 in vivo in certain circumstances
and help explain earlier conﬂicting results. An association with
plasma HIV-1 RNA level was not seen here when all levels of
A3-mediated hypermutation were analyzed, including subjects
with no detectable hypermutation in population sequences.
However, A3-mediated hypermutations in provirus DNA above
Y. Kourteva et al. / Virology 430 (2012) 1–96a threshold level (HI41) were inversely associated with plasma
viral load. Our longitudinal analysis of patient specimens over
time also adds evidence supporting an inverse association
between A3G and viremia level. The present study also extended
analyses to provirus burden. A3G, and not A3F, expression was
inversely associated with provirus burden. Hypermutation did not
account for this latter association, consistent with the extant
hypothesis that the deaminase-independent activities of A3G
affect provirus formation. Our results are not consistent with
the alternative hypothesis that A3 activity only adds genetic
diversity that beneﬁts replication of Vif-positive HIV-1 quasi-
species without impairing replication (Simon et al., 2005; Mulder
et al., 2008; Jern et al., 2009; Fourati et al., 2010; Kim et al., 2010).
It has been hypothesized that if greater functional A3 activities
provide a selective advantage against Vif-positive HIV-1 quasi-
species in vivo that is manifest over time, the distribution of A3
mRNA levels will be shifted toward higher levels in those untreated
subjects who survive longer (Jin et al., 2007). Indeed, if we consider
the higher CD4 cell count median of the LTNP subjects (614 cells/ml)
compared to that of the NC subjects (459 cells/ml) (Mann–Whitney
U test, p¼0.03) as a surrogate of duration of infection, this does
suggest an expected longer survival of the LTNP subjects, compared
to the NC subjects in this study. Thus, these results are consistent
with Jin et al.’s hypothesis (Jin et al., 2007).
Although RNA levels of A3F were similar to, and highly correlated
with, those of A3G, the predominance of A3G-targeted hypermuta-
tion suggests that either A3F protein levels or deaminase activity
were lower than those of A3G. Only one subject, a LTNP, had
hypermutation above that threshold level of HI41 in the provirus
dinucleotide targets of A3F as well as A3G. However, this one subject
had the greatest magnitude of hypermutation of all the subjects
studied, and also had markedly high A3F mRNA levels. One subject
in an earlier report had a similar A3F predominance (Kiljak et al.,
2008). The observed association of A3F RNA with A3G RNA might
explain the ﬁnding that A3F expression was associated with viremia
here. However, our data cannot exclude deaminase-independent
effects of A3F on viremia that are separate from those of A3G.
A3G and A3F are found either in a low molecular mass form or
in a high molecular mass complex in cells. Evidence suggests that
virion A3G is packaged from the low molecular mass form (Soros
et al., 2007). Further work will be needed to determine if
increases in one speciﬁc form are responsible for the inverse
association with HIV-1 replication, or if A3G differs from A3F in
the proportion of each form at higher cellular levels of expression.
Earlier studies also suggested antiviral effects of A3s against Vif-
positive HIV-1 in vivo. Jin et al. (2007) reported an inverse association
between A3G RNA levels in PBMCs activated ex vivo by anti-CD3/
CD28 antibodies and plasma HIV RNA levels in their analysis of
8 LTNP and 17 progressors who were antiretroviral naive (Jin et al.,
2005). They also found a positive association between A3G expression
and CD4 cell count (Jin et al., 2005). Ulenga et al. (2008a, 2008b) also
found that A3G mRNA levels were higher among infected subjects
with a low viral load set-point than those with a high viral load set-
point (Ulenga et al., 2008a, 2008b). Associations of A3G-mediated
PBMC DNA hypermutation with plasma HIV-1 RNA or CD4þ T cell
level consistent with an antiviral effect were also identiﬁed (Pace
et al., 2006; Land et al., 2008; Vazquez-Perez et al., 2009).
In our analyses, non-controllers had lower levels of A3 expres-
sion and fewer A3-hypermutated bases (after controlling for
the number of bases sequenced and the estimated rate of
RT-mediated mutation) than did subjects with spontaneous control
of HIV viremia. Adding data from subjects with HIo1 to our
analysis of the association of plasma viral load with provirus
hypermutation led to loss of the signiﬁcant effect seen when the
analysis was limited to subjects with HI41. This may help explain
why some reports did not identify an association with A3Gexpression (Cho et al., 2006) or hypermutation (Piantadosi et al.,
2009; Ulenga et al., 2008b). Each of those studies included unse-
lected, antiretroviral naı¨ve subjects among whom spontaneous
controllers might be infrequently found. Studying predominantly
non-controllers may have obscured an association.
Sequences of vif from high molecular weight PBMC DNA of LTNP
subjects had a greater mean number of hypermutated bases in A3G
target sequences than did sequences from NC subjects (determined
using Hyperpack software) (Kijak et al,. 2007; Kijak et al., 2008).
These results extends ﬁndings of earlier comparisons of controllers
versus non-controllers that associated hypermutation with sponta-
neous control of viremia (Vazquez-Perez et al., 2009; Pace et al.,
2006; Land et al., 2008) with a more quantitative analysis compar-
ing number of hypermutated positions. Another report found more
HIV-infected children with substantial PBMC hypermutation among
controllers than the non-controllers studied, although the differ-
ence in numbers of subjects was not statistically signiﬁcant in that
small sample with a predominance of A3F-mediated hypermuta-
tion; number of hypermutated positions was not compared
(Amoedo et al., 2011). As in that report, the larger number of LTNP
than NC subjects with HI41 did not reach statistical signiﬁcance
here. We speculate that the similarly small number of subjects in
each of these studies limited power (6 LTNP and 11 NC in Amoedo
et al., 2011; 12 LTNP and 7 NC in the present study).
In the current report, we compared analyses of population PCR
product sequences to that of molecular clones of PCR products
from 3 subjects. Almost all earlier studies of this topic used
population PCR product sequences (Pace et al., 2006; Land et al.,
2008; Vazquez-Perez et al., 2009; Ulenga et al., 2008b); only one
of the earlier reports analyzed 10 clones of PCR products from
each subject (Amoedo et al., 2011) and one sequenced multiple
single copy amplicons from each subject (Piantadosi et al., 2009).
As in the earlier report sequencing single copy amplicons that
found a range of 5–43% hypermutated sequences (Piantadosi
et al., 2009), we found 5–27% of cloned amplicons from high
molecular weight PBMC DNA with HIs41. This frequency of
hypermutated variants was detectable with population sequen-
cing. Clonal sequence results thus closely agreed with, and
validated the population PCR product sequencing. Because of this
close agreement and detectable frequency of hypermutated
variants, clonal sequencing was not performed on all subjects
studied here. This may be a limitation of the current study.
An earlier analysis of A3-mediated hypermutation did not ﬁnd
a difference between untreated elite suppressor (ES) subjects
versus subjects who were well suppressed on HAART (Gandhi
et al., 2008). This earlier work did not compare hypermutation in
HIV DNA in untreated subjects who spontaneously controlled
viremia to untreated subjects without such control of viremia, as
did our study and the others cited.
It has been suggested that hypermutation in proviruses may
be more obscured by greater ongoing replication of HIV and that
‘‘the ease of detection of hypermutated HIV-1 is likely a conse-
quence, rather than a cause, of LTNP status’’ (Simon et al., 2005).
Indeed, linear and episomal forms of lower molecular weight,
unintegrated HIV-1 DNA that are by-products of productive
replication are 10-fold more abundant than integrated provirus
in cells from untreated subjects (Koelsch et al., 2008). Physical
separation of high molecular weight DNA prior to ampliﬁcation
for population sequence analyses was done here to minimize the
possibility of artifactual underestimation of hypermutation in the
untreated NC subjects with presumed greater replication, based
on higher viremia levels, than the LTNP subjects. The GG HIs in vif
population sequences were also strongly correlated with A3G
expression levels (Fig. 3B), which would not be expected if the HI
differences were a artifactual consequence of relatively higher
levels of unintegrated DNA in NC subjects than LTNP subjects.
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relative to NC, in vivo. The latter ﬁnding is consistent with three
recent reports (Buzon et al., 2011; Graf et al., 2011; Saez-Cirion et al.,
2011) and was not studied in earlier work on A3s in vivo. Using an
alu-PCR assay from physically-separated genomic PBMC DNA that is
sensitive and speciﬁc for integrated genomes, a nearly 2-log differ-
ence in the median integrated provirus levels between the cells from
LTNP and NC subjects was noted here. The amount of integrated HIV
measured by alu-PCR here was stable over two time-points within
15 months apart. Changes in the amount of proviral DNA over time
were detected in only 2 of the 13 subjects (1 LTNP and 1 NC). DNA
from both of them harbored high levels of hypermutations, which
suggests that interference with PCR primer annealing may have
contributed to variability in repeated provirus estimates.
Increased A3G, but not A3F expression, was signiﬁcantly asso-
ciated with decreased provirus burden. The degree of hypermuta-
tion was not signiﬁcantly associated with provirus burden. This
supports the hypothesis raised by in vitro studies (Luo et al., 2007;
Mbias et al., 2010) that A3Gs’ deaminase-independent activity
contributes to the conﬁrmed cell-intrinsic block to HIV-1 provirus
formation in PBMCs of LTNPs in vivo and ex vivo (Graf et al., 2011;
Saez-Cirion et al., 2011; Buzon et al., 2011). Provirus burden was
directly associated with plasma viral load, consistent with its role
as a key measure of HIV replication. Since provirus GG HI41 was
inversely associated with plasma viral load, both types of A3G’s
functional activities (deaminase-independent and deaminase-
dependent) can contribute to spontaneous control of viremia.
One of a number of factors may contribute in different
individuals to spontaneous control of viremia. These factors
include innate or acquired immune responses, defective viruses,
defective host co-receptors and other host factors (Deeks and
Walker, 2007; Lambotte et al., 2005). Our ﬁndings suggest that
increased activity of A3G/F is one factor that can contribute to
spontaneous control of HIV-1 in vivo.
Either decreased Vif levels/activity or increased A3 levels/activity
could shift the balance in favor of deaminase-independent and -
dependent A3 activities in the infected cell. Although decreased Vif
activity due to mutation has been reported in clinical isolates and
associated with spontaneous control of HIV-1 in case reports (Simon
et al., 2005; Alexander et al., 2002; Farrow et al., 2005), mutations
were not identiﬁed in residues associated with Vif function in any of
the open Vif reading frames in replication competent HIV genomes in
our subjects. This, the higher A3G and A3F expression levels in LTNP
PBMCs relative to NC PBMCs, and the well established variation in
expression levels of A3 family members in different tissues (Koning
et al., 2009; Refsland et al., 2010), suggests that physiologically
increased cellular A3 levels and activities can provide therapeutic
beneﬁt against HIV-1 harboring functionally competent Vif in vivo. A
recent report that APOBEC3 induction during interferon-alpha treat-
ment of subjects coinfected with hepatitis C virus and HIV-1 was
correlated with degree of HIV DNA hypermutation adds support for
this concept (Pillai et al., 2012). In conclusion, our study indicates that
the higher expression levels, and both deaminase-dependent and
-independent activities, of the host restriction factor A3G can
contribute to long-term, spontaneous control of viremia in some
individuals.Materials and Methods
Study subjects and specimens
The study included 19 antiretroviral-naı¨ve HIV-1 positive indivi-
duals with plasma viral loads ranging from below 50 copies/ml to
56,841 copies/ml. The Vanderbilt Meharry CFAR HIV Immunopatho-
genesis Core provided cryopreserved PBMC from all subjects. Twelvesubjects were categorized as long-term non-progressors (LTNP)
because plasma viral load was consistently o5,000 copies/ml over
the prior 5 years. Seven subjects were non-controllers (NC) with
plasma VL410,000 copies/ml. Median (and IQR) VL for LTNP and
NC were 229 copies/ml (50–911) and 27,400 copies/ml (17,690–
49,770), respectively. Median (and IQR) CD4 counts for LTNP and NC
were 614/ml (527–1023) and 459/ml (300–553), respectively. Med-
ian age was 44 yrs (31–49) for LTNP and 47 yrs (41–55) for NC.
Specimens were available from 2 time-points within 15 months
from 9 of the LTNP and 4 of the NC.
RNA isolation and real-time PCR (qRT-PCR)
Viral RNA was isolated from frozen plasma samples according
to the instructions using QIAamp Viral RNA Kit (Qiagen, Valencia,
CA). Samples with viral load o1000 copies/ml were concentrated
by centrifugation at 25,000 g for 1hr before RNA isolation. Cellular
RNA was isolated from PBMC using RNeasy kit (Qiagen, Valencia,
CA) and quantiﬁed with RiboGreen RNA Quantitation Reagent and
Kit (Molecular Probes, Eugene, OR). After normalization by RNA
concentration, A3G/A3F transcripts were quantiﬁed by TaqMan
qRT-PCR (Applied Biosystems Prism 7000 Sequence Detection
System, Foster City, CA) using probes and primers developed in
our laboratory (Vetter et al., 2009b). Previous validation of the
real-time PCR showed o2.8 fold intra- and inter- assay variation.
Values are expressed as copies of transcripts normalized by 18S
and total RNA amount. It was previously noted that oligo-dT
primed cDNA synthesis for quantitative RNA PCR can under-
estimate A3F RNA quantity (Refsland et al., 2010; Amoedo et al.,
2011). In the present study, a speciﬁc primer was used to avoid
this known problem in quantifying A3F RNA.
Quantiﬁcation of HIV-1 provirus
HIV-1 proviral DNA was isolated from 1 million PBMC after
separating chromosomal and viral unintegrated DNA in the
presence of 1 M NaCl and 0.6% SDS (Hirt, 1967). Cellular genomic
DNA was further puriﬁed with the Genomic DNA Puriﬁcation Kit
(Gentra Systems, Minneapolis, MN). A modiﬁed 2-step Alu PCR
assay quantiﬁed integrated proviral copy numbers (O’Doherty
et al., 2002). In the ﬁrst step, integrated HIV-1 sequences were
ampliﬁed with a mix of genomic Alu primers (50-TCC CAG CTA CTC
GGG AGG CTG AGG and 50-GCC TCC CAA AGT GCT GGG ATT ACA G)
and HIV-1 PBS primer (50-TTT CAG GTC CCT GTT CGG GCG CCA)
using 180 ng of human genomic DNA, 200 nM of each dNTP, and 2 U
of rTth DNA polymerase (Applied Biosystems, Foster City, CA).
The reaction was run initially for 3 min at 94 1C and for 15 cycles
of 30 s at 94 1C, 30 s at 65 1C and 3min at 70 1C, with a ﬁnal
extension for 10 min at 72 1C. Negative and background one way
control ampliﬁcations were performed either with no primers, or
with only HIV-1 PBS primer. ACH-2 cells were used as HIV-1 DNA
copy number standard in a constant DNA background. DNA prepared
from CEM cells mixed with graded doses of ACH-2 cells (NIH AIDS
Research and Reference Reagent Program, Division of AIDS, NIAID,
NIH) was ampliﬁed with the primers used in the ﬁrst step and used
for the standards in the second quantitative PCR step. To increase the
sensitivity and accuracy of the assay, 6 Alu-PCR reactions were
performed with each DNA sample. The ﬁrst-step amplicon mix
was diluted 50-fold for the second step real-time PCR to quantify
HIV LTR sequences. This used TaqMan Universal PCR Master Mix
(Applied Biosystems Foster City, CA) with 2 ml of the diluted ﬁrst
ampliﬁcation product, 500 nM of each primer (forward primer:
50-CCT GGG AGC TCT CTG GCT AA-30, reverse primer: 50-GCA CTC
AAG GCA AGC TTT ATT GA-30) and 100 nM probe (6FAM-TAGG-
GAACCCACTGCTTA-MGBNFQ). The template was denatured for
10 min at 95 1C followed by 40 cycles consisting of 15 s at 95 1C
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(Applied Biosystems, Foster City, CA). The coefﬁcient of variation
(CV) between replicates in the second step was o50%.
Sequencing
Plasma HIV-1 RNA was reversed-transcribed with OmniScript RT
(Qiagen, Valencia, CA) using speciﬁc primers for the region of
interest. Nested PCRs were performed to separately amplify both
the 999-bp fragment ﬂanking Vif and the 1307-bp Pol region
including protease and part of RT. Primers were designed to anneal
to sites lacking A3G/F consensus targets and primer mixes including
matches to both hypermutated and non-hypermutated positions
were used when that was not possible. For population-based
sequencing, PCR amplicons were directly sequenced using ABI Prism
BigDye terminator cycle sequencing kit (Applied Biosystems, Foster
City, CA) and speciﬁcally designed inner PCR primers. For clonal
sequencing, PCR products were TA cloned into the TOPO-2.1 vector
(Invitrogen, Carlsbad, CA) and 10–15 clones were sequenced for each
sample. ABI Prism 3100 genetic analyzer was used for all sequencing
and resulting electropherograms were assembled using Sequencher
4.8 software (Gene Codes Corp, Ann Arbor, MI). GeneBank accession
numbers are JQ409018 to JQ409041.
Hypermutation analysis
The extent of hypermutation was quantiﬁed by 3 different
parameters: hypermutation index (HI) using Hyperpack, a statisti-
cally signiﬁcant difference from the level in the reference sequence
determined with Hypermut 2.0, and premature stop codons in HIV-
1 open reading frames due to G to A mutation using Hyperpack
(Rose and Korber, 2000; Kijak et al., 2007; Kijak et al., 2008).
Hyperpack calculates a hypermutation index (HI) as G-to-A sub-
stitutions per base pair minus the A-to-G substitutions per base pair
divided by the sequence length in base pairs. This uses the level of
A-to-G substitution to correct for background mutation rate due to
factors other than A3 activity. Dinucleotide contexts of G-to-A
hypermutations were also analyzed with the Hyperpack software
(Kijak et al., 2007). GG HI and GA HI were determined by the levels
of GG to AG and GA to AA substitutions respectively per 100 bp
sequences. G-to-A hypermutation was also analyzed using Hyper-
mut 2.0 (Rose and Korber, 2000 and www.hiv.lanl.gov/content/
sequence/HYPERMUT/hypermut.html) which compares the hyper-
mutated sequence to a reference sequence and evaluates statistical
signiﬁcance of a difference from the reference by Fisher’s exact test.
It does not speciﬁcally compare G-to-A changes to A-to-G changes to
adjust for background mutation, nor does it normalize number of
mutated G’s over a speciﬁc number of bases.
G to A mutations were not found in sequences derived from
plasma HIV-1 RNA, as others have noted (Kieffer et al., 2005; Land
et al., 2008). Therefore, we used a non-hypermutated sequence
from plasma HIV-1 RNA from the same subject as a comparison,
except for one subject, a LTNP with undetectable viremia, for
whom a non-hypermutated sequence derived from PBMC proviral
DNA was used. The non-hypermutated reference sequence for
each subject was conﬁrmed to be phylogenetically related to the
same parental virus as the hypermutated variants. Hypermuta-
tion was greater by both HI and the Hypermut analysis criteria
when the single reference HXB2 sequence, rather than an indiv-
dual subject’s reference, was used (data not shown).
Statistical analysis
Correlations were assessed by Spearman’s rank correlation
coefﬁcients. Two-tailed, unpaired Student’s t test compared dis-
tributions of continuous variables between two groups withstatistical signiﬁcance at po0.05. Medians of hypermutated
positions in vif sequences were compared between LTNP and NC
subjects by one-tailed Mann–Whitney U test with statistical
signiﬁcance at po0.05 because the hypothesis suggested by the
majority of earlier studies was that there would be more hyper-
mutated positions among LTNP subjects and this was supported
by our results showing higher A3 expression among LTNP sub-
jects. Fisher’s exact test compared the number of subjects with
HI41 among LTNP versus NC.Acknowledgments
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